drugset / Trial / NCT05057923

The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores

NCT05057923

Completed 9 enrolled DreamTec Research Limited
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.

Timeline

Start
2021-07-10
Primary completion
2021-10-20
Completion
2021-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bacillus subtilis Vaccine 1e+10 unknown Oral
Subject Bacillus subtilis Vaccine 1e+11 unknown Oral

Indications